Related to Review of the Second Tier of Biotechnology Clusters in the U.S.

• Voters Divided on What Congress Will Do About NIH in FY 2012
  
• New York Genome Center Expected to Boost City's Biotech Presence
  
• Readers Divided on Obama Administration’s Helpfulness to Biopharma During 2011
  
• Biopharma Investment Grows During Q4 but VCs Fund Fewer Early Deals
  
• Growth of Corporate Ventures Reflected in Rising VC Numbers
  
• President Obama Restates Case for Basic Research in State of the Union Address
  
• NIH Won’t Survive FY 2013 Without Budget Reduction, GEN Poll Predicts
  
• Biogen Idec Explains Company’s Move Away from Venture Funding
  
• Moffitt Cancer Center, Sanford-Burnham, and Florida Hospital Forge Pact
  
• Uncertainty Surrounds Proposed 2013 Budget for FDA and CDC, GEN Poll Suggests
  
• Poll Respondents Undecided About Helpfulness of President's Proposed Budgets for NIH, NSF
  
• Russian Tech Fund Joins U.S. VC Firm in $760M Biopharma Venture
  
• Index Ventures Launches €150M Life Sciences Fund with GSK, J&J
  
• Merck & Co. Joins VC Firms to Initiate R&D Fund in Quebec
  
• Poll Majority Confident that Massachusetts Can Maintain Biopharma Construction Boom
  
• House, Senate Propose Budget Breakdown for NSF, NIST, and OSTP
  
• Senate Appropriations Approves FDA Budget for FY 2013
  
• More than Half of GEN Poll Respondents Side With President Obama Over Ryan on Budget Size
  
• GEN Poll Respondents ‘Somewhat’ Optimistic VC Market Will Improve This Year
  
• Poll Respondents Divided on Impact of FDA Legislation on Investing Environment